The present invention has an object to provide a compound which has excellent compatibility even with a cellulose ester resin having a low acetylation degree, is capable of providing an optical film having a high Rth value and high bleed resistance, and can be suitably used as a retardation enhancer; a cellulose ester resin composition including the compound; an optical film including the resin composition; and a liquid-crystal display device including the optical film. The present invention provides an epoxy ester compound represented by the following Formula (1) (in the formula, R.sup.1 to R.sup.4 each independently represent an alkyl group having 1 to 3 carbon atoms; and A's each represent an aromatic group (a1) or an aliphatic group (a2) having 1 to 4 carbon atoms, and the average presence ratio [(a1)/(a2)] of the aromatic groups (a1) to the aliphatic groups (a2) is 99.9/0.1 to 80/20 in terms of a molar ratio).

The present invention has an object to provide a compound which has excellent compatibility even with a cellulose ester resin having a low acetylation degree, is capable of providing an optical film having a high Rth value and high bleed resistance, and can be suitably used as a retardation enhancer; a cellulose ester resin composition including the compound; an optical film including the resin composition; and a liquid-crystal display device including the optical film. The present invention provides an epoxy ester compound represented by the following Formula (1) (in the formula, R.sup.1 to R.sup.4 each independently represent an alkyl group having 1 to 3 carbon atoms; and A's each represent an aromatic group (a1) or an aliphatic group (a2) having 1 to 4 carbon atoms, and the average presence ratio [(a1)/(a2)] of the aromatic groups (a1) to the aliphatic groups (a2) is 99.9/0.1 to 80/20 in terms of a molar ratio).

The present technology relates to synthesis of resveratrol compositions, in particular to methods of synthesizing resveratrol salicylates such as those formed through the activation of resveratrol and salicylic acid, and cosmetic and pharmaceutical compositions comprising the same.

The present technology relates to synthesis of resveratrol compositions, in particular to methods of synthesizing resveratrol salicylates such as those formed through the activation of resveratrol and salicylic acid, and cosmetic and pharmaceutical compositions comprising the same.

The present technology relates to synthesis of resveratrol compositions, in particular to methods of synthesizing resveratrol salicylates such as those formed through the activation of resveratrol and salicylic acid, and cosmetic and pharmaceutical compositions comprising the same.

An organic film composition including a compound represented by the following general formula (1), ##STR00001## wherein n1 and n2 each independently represent 0 or 1; “W” represents a single bond or any of structures represented by the following formula (2); R.sub.1 represents any of structures represented by the following general formula (3); m1 and m2 each independently represent an integer of 0 to 7, with the proviso that m1+m2 is 1 to 14. ##STR00002##
There can be provided an organic film composition for forming an organic film having dry etching resistance as well as advanced filling/planarizing characteristics.

An organic film composition including a compound represented by the following general formula (1), ##STR00001## wherein n1 and n2 each independently represent 0 or 1; “W” represents a single bond or any of structures represented by the following formula (2); R.sub.1 represents any of structures represented by the following general formula (3); m1 and m2 each independently represent an integer of 0 to 7, with the proviso that m1+m2 is 1 to 14. ##STR00002##
There can be provided an organic film composition for forming an organic film having dry etching resistance as well as advanced filling/planarizing characteristics.

The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

The present technology relates to synthesis of resveratrol compositions, in particular to methods of synthesizing resveratrol salicylates such as those formed through the activation of resveratrol and salicylic acid, and cosmetic and pharmaceutical compositions comprising the same.